The Effect of Semaglutide on the Intestinal Flora in Obesity

Inclusion criteria

• 18 to 60 years old;
• BMI ≥ 30kg/m²;
• At least one self-reported history of unsuccessful lifestyle weight loss;
• Subjects who agree to participate in the project and sign the informed consent form.

Exclusion criteria

• Weight changes within 3 months prior to screening (self-reported) >5%;
• Having received any drug treatment for obesity within the three months prior to screening;
• The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;
• Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening;
• Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc;
• Triglycerides ≥500mg/dL (5.65mmol/L) during screening;
• It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history;
• Abnormal thyroid function;
• History of mental illness;
• History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg/mL;
• Abnormal liver function during screening, that is, alanine aminotransferase and/or aspartate aminotransferase > 3*ULN;
• Abnormal renal function during screening, that is, the estimated glomerular filtration rate is less than 60mL/min/1.75m2;
• History of cardiovascular diseases;
• History of malignant tumors;
• Pregnancy or lactation;
• As determined by the researcher, there are other physical, psychological or other conditions that make one unsuitable to participate in the trial.